The weekly litigation news digest is live. Subscribe now

Patent Oppositions in organic compounds as pharmaceutical ingredients industry

Explore the competitive field of organic compounds as pharmaceutical ingredients where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in organic compounds as pharmaceutical ingredients technology and learn how to protect your intellectual property.

Get Patent Opposition Report for organic compounds as pharmaceutical ingredients

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the organic compounds as pharmaceutical ingredients industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the organic compounds as pharmaceutical ingredients industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 20, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name
Urolithin A And A Composition Containing Same For External Use In Inflammations Of Various EtiologiesMICROBIOTA MED SP Z OOOct 15, 2025AMAZENTIS
Methods Of Reducing The Risk Of Cardiovascular Events In A SubjectAMARIN PHARMACEUTICALS IRELANDJan 24, 2025ELKINGTON AND FIFE
Methods For Treating Diseases Using Isoindoline CompoundsAMGEN EUROPENov 16, 2021TEVA PHARMACEUTICALS
Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer TreatmentIPSEN BIOPHARMSep 9, 2021SANDOZ
Process For Manufacturing Chewable Dosage Forms For Drug Delivery And Products ThereofBAYERJun 22, 2021BOEHRINGER INGELHEIM
Improved Methods For Preparing SqualeneNOVARTISApr 15, 2021GLAXOSMITHKLINE
Topical Oil Composition For The Treatment Of Fungal InfectionsVYOME BIOSCIENCES PVTMar 24, 2021THE PROCTER & GAMBLE
Topical Oil Composition For The Treatment Of Fungal InfectionsVYOME THERAPEUTICSMar 4, 2021HENKEL
Semi-Synthetic Or Synthetic VaselinesAIGLONJul 16, 2020SASOL WAX
Manufacture Of An Oil-In-Water Emulsion Comprising SqualeneNOVARTISNov 6, 2019GLAXOSMITHKLINE

To stay ahead in the competitive organic compounds as pharmaceutical ingredients industry, companies are constantly innovating. Here are the top patents facing oppositions in the organic compounds as pharmaceutical ingredients industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleApplicantTotal Oppositions
Jun 24, 2020Topical Oil Composition For The Treatment Of Fungal InfectionsVYOME THERAPEUTICS3
Oct 16, 2019Semi-Synthetic Or Synthetic VaselinesAIGLON1
Feb 6, 2019Manufacture Of An Oil-In-Water Emulsion Comprising SqualeneSEQIRUS UK1
Jun 20, 2018Ointments For The Topical Treatment Of PsoriasisLEO PHARMA1
Feb 17, 2021Methods For Treating Diseases Using Isoindoline CompoundsCELGENE1
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer TreatmentIPSEN BIOPHARM1
Jul 15, 2020Improved Methods For Preparing SqualeneNOVARTIS1
Jan 15, 2025Urolithin A And A Composition Containing Same For External Use In Inflammations Of Various EtiologiesWARSZAWSKI UNIWERSYTET MEDYCZNY1
Dec 23, 2020Process For Manufacturing Chewable Dosage Forms For Drug Delivery And Products ThereofBAYER1
Apr 24, 2024Methods Of Reducing The Risk Of Cardiovascular Events In A SubjectAMARIN PHARMACEUTICALS IRELAND1